Bipolar patients with mania/mixed episodes who quit using cannabis do better than their counterparts who continue using the drug, new research shows. Investigators at the International Mood Disorders ...

Credit: Getty Images. Lumateperone 42mg given once daily met the primary endpoint in the study. Lumateperone monotherapy was associated with significant improvement of major depressive episodes in ...

The approval of medicines called second-generation antipsychotics has allowed bipolar I and other associated conditions to be treated. A person with bipolar I disorder can go through various mood ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Fanapt tablets for the acute treatment of manic or mixed episodes associated with bipolar I ...

NEW YORK, March 28, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies (ITCI), Inc. , a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous ...

An antipsychotic approved by the FDA in 2009 to treat schizophrenia has now been green-lighted for use in bipolar 1 disorder. Iloperidone (Fanapt) is now FDA-approved for adults with bipolar 1 ...

Fifteen years after gaining its first FDA approval for Fanapt (iloperidone) to treat schizophrenia, Vanda Pharmaceuticals has scored again with the same antipsychotic drug. The FDA has signed off on ...

Yesterday, I couldn’t stand being inside my skin. It felt like a prison, this body of mine that didn’t know what it wanted or why it was here. I squirmed through the day, fussing and eating and eating ...

Bipolar disorder exists on a spectrum rather than as a single, uniform condition. This fundamental characteristic explains why two people with the same diagnosis can experience dramatically different ...

Patients treated with iloperidone had significantly larger improvements vs placebo based on the change from baseline in the Young Mania Rating Scale total score. The Food and Drug Administration (FDA) ...

Over the past three weeks, we've lifted the masks of many Major Depressive Disorder (MDD) presentation variations. Today, we'll investigate Mixed Features before moving onto specifiers of onset.